Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 11/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25728007 | 0.91 | MDM2 (0.55) | ALBMDM2TLR2KMT2A | |
| SCHEMBL30905431 | 0.90 | ALB (0.53) | ALBMDM2TLR2CA9KMT2A | |
| SCHEMBL22021737 | 0.90 | MDM2 (0.57) | ALBMDM2TLR2KMT2A | |
| SCHEMBL20530026 | 0.89 | ALB (0.53) | ALBMDM2TLR2CA9KMT2A | |
| SCHEMBL24193189 | 0.89 | MDM2 (0.55) | ALBMDM2TLR2KMT2A | |
| SCHEMBL21963412 | 0.89 | MDM2 (0.55) | ALBMDM2TLR2KMT2A | |
| SCHEMBL22021738 | 0.87 | MDM2 (0.56) | ALBMDM2TLR2KMT2A | |
| SCHEMBL24193273 | 0.86 | MDM2 (0.55) | ALBMDM2TLR2KMT2A | |
| SCHEMBL15964082 | 0.86 | TLR2 (0.49) | ALBMDM2TLR2CA9KMT2A | |
| SCHEMBL14708957 | 0.86 | ALB (0.47) | ALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | ALB 3527/4885MDM2 1169/4885TLR2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.